EGFR and non-small cell lung carcinoma: This study investigated plasma metabolite profiles across four groups: 29 NSCLC patients with EGFR mutations, 29 without EGFR mutations, 10 patients resistant to EGFR-targeted therapy (TKI-resistant), and 10 healthy controls.